Results 31 to 40 of about 30,927 (236)

Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? [PDF]

, 2017
INTRODUCTION: Recent genetic and molecular discoveries regarding alterations in diffuse large B-cell lymphoma (DLBCL) deeply changed the approach to this lymphoproliferative disorder.
Ansuinelli, Michela, DE ANGELIS, Federico, DI ROCCO, Alice, Foa, Roberto, Martelli, Maurizio   +4 more
core   +1 more source

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. [PDF]

, 2017
BackgroundThe CXCR4-CXCL12 axis plays an important role in the chronic lymphocytic leukemia (CLL)-microenvironment interaction. Overexpression of CXCR4 has been reported in different hematological malignancies including CLL.
Amaya-Chanaga, Carlos I, Amine, Ale-Ali, Castro, Januario E, Choi, Michael Y, Fantin, Valeria R, Gu, Yin, Hallin, Max, Huser, Nanni, Kashyap, Manoj K, Kipps, Thomas J, Kumar, Deepak, Lindquist, Kevin, Liu, Shu-Hui, Pernasetti, Flavia, Rassenti, Laura Z, Simmons, Brett, Smeal, Tod, Yafawi, Rolla, Zhang, Cathy   +18 more
core   +4 more sources

CD86, the double agent: Significance of CD86 expression in B-cell malignancies. [PDF]

Int J Cancer
Abstract Bypassing the anti‐tumor functions of the immune system is one of the keys to tumor survival. Tumors, especially hematological tumors, produce or express factors that retune T and B cells to inhibit the immune response. Coreceptors CD28 and CTLA‐4, and their ligands, CD80 and CD86, are involved in the immunological synapse and play an ...
Barna G, Szalóki G, Márk Á, Hunyadi A, Kriston C.   +4 more
europepmc   +2 more sources

Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction [PDF]

, 2018
The MEK inhibitors cobimetinib and trametinib are used in combination with BRAF inhibitors to treat metastatic melanoma but increase rates of hemorrhage relative to BRAF inhibitors alone.
Bye, Alex P., Donaghy, Dillon, Gibbins, Jonathan M., Kriek, Neline, Osborne, Ashley A., Sage, Tanya, Unsworth, Amanda J.   +6 more
core   +4 more sources

Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement [PDF]

, 2017
Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies. BTK was initially shown to be defective in the primary
Doorduijn, J.K. (Jeanette), Hiemcke-Jiwa, L.S. (Laura S.), Huibers, M.M.H. (Manon M. H.), Leguit, P. (Piet), Minnema, M.C. (Monique), Radersma-van Loon, J.H. (Joyce H.), Rood, J.J.M. (Johannes J. M.), Westerweel, J. (Jerry)   +7 more
core   +10 more sources

Ibrutinib:
From Molecule to Medicine

International Journal of Hematology and Oncology, 2014
Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is a novel targeted-therapeutic agent modulating BCR, which serves as a covalent irreversible inhibitor of BTK. Ibrutinib significantly alters the composition of the tumor microenvironment in CLL, affecting soluble as well as cellular molecular elements without myelosupression. Ibrutinib is
Demirkan, Fatih, Ayyildiz, Orhan, Unal, Ali, KAYNAR, Leylagül, Vural, Filiz, Turgut, Mehmet, ŞAHİN, FAHRİ, SAYINALP, NİLGÜN, SAYDAM, GÜRAY, Ozdemir, Evren, Ilhan, Osman, Haznedaroglu, Ibrahim C., GÖKER, HAKAN   +12 more
openaire   +4 more sources

The cytoskeletal control of B cell receptor and integrin signaling in normal B cells and chronic lymphocytic leukemia

FEBS Letters, EarlyView.
In lymphoid organs, antigen recognition and B cell receptor signaling rely on integrins and the cytoskeleton. Integrins act as mechanoreceptors, couple B cell receptor activation to cytoskeletal remodeling, and support immune synapse formation as well as antigen extraction.
Abhishek Pethe, Tanja Nicole Hartmann
wiley   +1 more source

B cell mechanobiology in health and disease: emerging techniques and insights into therapeutic responses

FEBS Letters, EarlyView.
B cells sense external mechanical forces and convert them into biochemical signals through mechanotransduction. Understanding how malignant B cells respond to physical stimuli represents a groundbreaking area of research. This review examines the key mechano‐related molecules and pathways in B lymphocytes, highlights the most relevant techniques to ...
Marta Sampietro, Marco Cellani, Cristina Scielzo   +2 more
wiley   +1 more source

Targeting Brutons Tyrosine Kinase in Chronic Lymphocytic Leukemia at the Crossroad between Intrinsic and Extrinsic Pro-survival Signals [PDF]

, 2016
Chemo immunotherapies for chronic lymphocytic leukemia (CLL) showed a positive impact on clinical outcome, but many patients relapsed or become refractory to the available treatments.
Facco, Monica, Frezzato, Federica, Martini, Veronica, Semenzato, Gianpietro, Severin, Filippo, Trentin, Livio, Trimarco, Valentina, Visentin, Andrea   +7 more
core   +1 more source

Single‐cell insights into the role of T cells in B‐cell malignancies

FEBS Letters, EarlyView.
Single‐cell technologies have transformed our understanding of T cell–tumor cell interactions in B‐cell malignancies, revealing new T‐cell subsets, functional states, and immune evasion mechanisms. This Review synthesizes these findings, highlighting the roles of T cells in pathogenesis, progression, and therapy response, and underscoring their ...
Laura Llaó‐Cid
wiley   +1 more source